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Chitosan and alkalinizing agents can decrease morbidity and mortality in humans with chronic kidney disease (CKD). Whether
this holds true in dog is not known. Objective of the study was to determine whether a commercial dietary supplement containing
chitosan, phosphate binders, and alkalinizing agents (Renal), compared to placebo, reduces mortality rate due to uremic crises in
dogs with spontaneous CKD, fed a renal diet (RD). A masked RCCT was performed including 31 azotemic dogs with spontaneous
CKD. Dogs enrolled in the study were randomly allocated to receive RD plus placebo (group A; 15 dogs) or RD plus Renal (group
B; 16 dogs). During a ﬁrst 4-week period, all dogs were fed an RD and then randomized and clinically evaluated up to 44 weeks.
The eﬀects of dietary supplements on mortality rate due to uremic crises were assessed. At 44 weeks, compared to group A, dogs
in group B had approximately 50% lower mortality rate due to uremic crises (P = 0.015). Dietary supplementation with chitosan,
phosphate binders, and alkalinizing agents, along with an RD, is beneﬁcial in reducing mortality rate in dogs with spontaneous
CKD.
1.Introduction
There is a strong consensus to use dietary modiﬁcation
in dogs aﬀected by chronic kidney disease (CKD) [1–7].
Feeding a renal diet (RD) in dogs with mild and moderate
spontaneous CKD had beneﬁcial eﬀects on uremia and mor-
tality rate compared to a maintenance diet [1]. In addition,
phosphate retention and renal secondary hyperparathy-
roidism are common complications of CKD [2–7], and
hyperphosphatemia is associated with the development of
renal lesions in dogs and cats [2–7]. In humans and cats,
oral supplementation with compounds such as chitosan
(produced by deacetylation of chitin, which is the structural
element in the exoskeleton of crustaceans and cell wall of
fungi), calcium carbonate, and potassium citrate has been
advocated to control hyperphosphatemia [4–11]. In addi-
tion, chitosan is recognized to reduce azotemia during spon-
taneous CKD in humans and cats [8–10]. However, whether
this holds true for dog has not been previously assessed.
Aim of the present study was to evaluate the eﬃcacy of a
commercial oral supplement rich in chitosan, enteric phos-
phate binders, and alkalinizing agents (Renal—Istituto Far-
maceutico Candioli SpA, Italy), in reducing mortality rate
d u et ou r e m i cc r i s e si nd o g sa ﬀected by spontaneous CKD,
in International Renal Interest Society (IRIS) stages 2, 3, and
4[ 4, 12], fed an RD.
2.MaterialsandMethods
2.1. Animals. Dogs aﬀected by CKD, in IRIS stages 2, 3,
and 4, were recruited at the Clinica Veterinaria Pirani of
Reggio Emilia, Italy. Results of history, physical examination,
includingbodyweight(BW)andbodyconditionscore(BCS)
(1 to 5 scoring system (3 optimal)), CBC, serum biochemical
proﬁle, urinalysis, urine protein-to-creatinine (UPC) ratio,
venous blood gas analysis, and indirect blood pressure2 The Scientiﬁc World Journal
measurement were collected. All dogs underwent abdominal
ultrasonographic examination, which was performed by
the same operator and with the same instrument (Philips
HD11XE or Philips HD7XE, Philips Ultrasound, Bothell,
Washington, USA). Dogs of any age were included if pre-
senting inactive urine sediment and stable renal function, as
deﬁned by serum creatinine concentrations above 1.4mg/dL
(IRIS stages ≥ 2) that did not increase or decrease by 20% or
more within 4 weeks from initial determination [4]. In the
ﬁrst 4-week period, all dogs were started on an RD (Royal
Canin Renal Canine, Royal Canin SA, Aimargues, France;
Hill’s Prescription Diet Canine k/d, Hill’s Pet Nutrition Inc,
Topeka, Kansas, USA).
Dogs were excluded if clinically aﬀected or suspected to
be aﬀected by genitourinary tract inﬂammation or infec-
tion, cardiac disease, neoplasia, and endocrinopathies. As a
standard, dogs with arterial pressure (AP) substage 3 of the
IRIS staging system [12] were treated with oral amlodipine
at 0.1 to 0.5mg/kg, q 24hr, in order to reduce AP to substage
1o r0[ 6, 7, 13, 14]. Dogs with serum albumin concentra-
tion ≤ 2.0g/dL received oral acetylsalicylic acid at 2.0mg/kg
q 24hr, to prevent thrombosis [6] (Shearer L, Kruth SA,
Wood D. Eﬀects of aspirin and clopidogrel on platelet func-
tion in healthydogs. J Vet Intern Med 2009; 23(3): 745 (ab-
stract)).
2.2. Study Design. A randomized, blinded, placebo-con-
trolled clinical trial was performed using a software to allo-
cate cases (MedCalc, Version 11.3.0.0). Informed consent to
participate in the study was signed by dog owners.
In the ﬁrst 4 weeks following inclusion all dogs were
started on an RD (Royal Canin Renal Canine, Royal Canin
SA, Aimargues, France; Hill’s Prescription Diet Canine k/d,
Hill’s Pet Nutrition Inc, Topeka, Kansas, USA). At the end
of this ﬁrst period, all dogs were clinically reevaluated, per-
forming all above-mentioned laboratory and instrumental
analyses and assigned to group A (RD plus placebo), or
treatmentgroupB(RDplusRenal).Compositionsofthedie-
tary supplements are provided in Table 1.
To mask the identity of the two supplements, they were
formulated as powders with identical colours and contained
in the same package. After assignment to group A and B,
dogs were reassessed between week 4 and 8. Thereafter,
examinations were scheduled every 4 months and up to 44
weeks of treatment, or earlier if worsening of clinical signs
was noted by the owner.
2.3. Blood Sampling and Assay. During each examination,
a blood sample was collected in overnight fasted dogs, and
serum was obtained within 30 minutes, stored at 4◦Ca n d
analyzed within 24 hours. Venous blood gas analysis (Rapid-
point 400, Bayer Health Care, Tarrytown (NY), USA) was
immediately performed in all cases.
CBCandserumbiochemicalanalysis,includingalbumin,
total protein, glucose, bilirubin, cholesterol, amylase, ala-
nine transferase, alkaline phosphatase, blood urea nitrogen
(BUN), creatinine, ionized calcium, sodium, potassium,
chloride, and phosphate, were determined by the use of
standard methods (Cobas Mira, Roche Diagnostic, Basel,
Table 1: Composition of placebo and Renal.
Placebo
Maltodextrin
Renal
Maltodextrin
Calcium carbonate (Ca 38%)
Potassium Cytrate (K 36%)
Chitosan
Switzerland). Blood samples were labelled with alphanu-
meric codes assigned by randomization to ensure that lab-
oratory personals were blinded during processing. All of
the above-mentioned biochemical parameters were used for
inclusion and exclusion evaluation.
2.4. Urine Sample and Urinalysis. During abdominal ultra-
sonography, an echo-guided cystocentesis was performed in
all dogs, by the use of a 5mL syringe connected to a 23-
gauge needle. All urine samples were put in 10mL, sterile,
evacuated collection tubes labelled with alphanumeric codes
based on the previous randomization. All urine samples
were analyzed by the same operator. Urines were examined
within 60 minutes from collection if samples were stored
at room temperature (approx. 20◦C), or within 4 hours
if samples were stored at 4◦ to 8◦C. Urine sediment was
obtained by centrifugation (10 minutes at900 ×g) of 5mL of
urine, followed by removal of 4.5mL of supernatant, and by
resuspension of the remaining 0.5mL of urine. A sample of
12µL of the resuspended urine was microscopically assessed.
The supernatant was transferred into separate tubes and
stored at −20◦C to determine urine protein and creatinine
concentrationwithin7days.RBCsandWBCswereexpressed
as mean number of cells/10hpf (40x magniﬁcation). Urine
sediment with bacteriuria, and/or >5 RBCs or WBCs/hpf,
was considered indicative of active inﬂammation.
2.5. UPC Ratio. To calculate the UPC ratio, protein concen-
tration (mg/dL) was measured with pyrogallol red, and crea-
tinine (mg/dL) was measured by the use of the Jaﬀ´ e method
in undiluted urine that was thawed before the analysis.
Analytes were measured in an automated spectrophotometer
(Cobas Mira, Roche Diagnostic, Basel, Switzerland). Dogs
were classiﬁed as nonproteinuric, borderline proteinuric,
or proteinuric according to the IRIS staging system (UPC
ratio < 0.2 = nonproteinuric, UPC ratio 0.2 to 0.5 = border-
line proteinuric, and UPC ratio > 0.5 = proteinuric) [4, 12].
2.6. Blood Pressure Measurement. Systolic blood pressure
measurements were obtained by the use of an ultrasonic
Doppler device (DOP 2001, SAMED Elettromedicali srl,
M e r l i n o( L O ) ,I t a l y )i na l ld o g s[ 13, 14].
2.7. Diagnosis of Uremic Crisis. Diagnosis of uremic crisis
wasestablishedbycliniciansinvolvedinpatientmanagement
unaware of the supplement being administered. As previ-
ously suggested by Jacob and colleagues [1], uremic crisisThe Scientiﬁc World Journal 3
Table 2: Mean, median, and 25% and 75% for BW and BCS, hematocrit, serum creatinine, BUN, phosphate, blood pH, bicarbonate,
and UPC ratio, for Group A and B at time of randomization. Diﬀerences between groups are depicted by P value (statistically signiﬁcant
P<0.05).
Group A Group B P value (A Versus B)
BW (kg)
mean 18.2 21.0
median 14.4 17.8 0.17
25% percentile; 75% percentile (8.5; 29.0) (9.7; 29.9)
BSC (1–5)
mean 2.8 2.7
median 3.0 3.0 1.00
25% percentile; 75% percentile (3.0; 3.0) (2.0; 3.0)
Serum Creatinine (mg/dL)
mean 5.7 4.9
median 3.1 4.1 0.66
25% percentile; 75% percentile (1.9; 10.5) (2.1; 7.23)
BUN (mg/dL)
mean 97.1 86.2
median 69.0 75.1 0.76
25% percentile; 75% percentile (32.2; 204.0) (42.9; 150.1)
Phosphorus (mg/dL)
mean 8.9 7.1
median 7.2 7.2 0.90
25% percentile; 75% percentile (5.4; 11.0) (5.0; 9.5)
Blood pH
mean 7.30 7.29
median 7.30 7.34 0.55
25% percentile; 75% percentile (7.25; 7.40) (7.20; 7.39)
HCO3− (mEq/L)
mean 18.9 18.4
median 19.1 18.2 0.14
25% percentile; 75% percentile (16.0; 23.4) (14.6; 22.7)
Hct (%)
mean 30.7 32.1
median 34.00 33.0 0.37
25% percentile; 75% percentile (24.6; 39.0) (24.5; 41.0)
UPC ratio
mean 2.90 0.62
median 0.68 0.39 0.41
25% percentile; 75% percentile (0.24; 1.60) (0.29; 0.80)
was deﬁned when the 3 following ﬁndings were observed:
(i) identiﬁcation of at least 2 clinical signs consistent with
uremia including depression, lethargy, anorexia, vomiting,
uremic breath odour; (ii) serum creatinine concentration at
least 20% greater than the previously determined value; (iii)
no plausible alternative for these clinical signs.
2.8. Establishing Cause of Death. Causes of death were cate-
gorized as nonrenal, probably renal or renal, based on results
of anamnesis, physical examination, blood and urine tests,
and criteria used to deﬁne uremic crisis. To avoid bias, only
dogs classiﬁed in the third category were considered to have
died from a renal event (uremic crisis). Necropsies were not
performed in any case.
2.9. Statistical Analysis. Dogs characteristics between groups
were compared at the time of group assignment, and
intragroup during reexamination at 4–8 weeks of treatment,
using the Mann-Whitney nonparametric test. We statis-
tically evaluated the following parameters: BCS and BW,
hematocrit, serum creatinine, BUN, phosphate, blood pH,
bicarbonate, and UPC ratio.
Kaplan-Meier was used to evaluate the survival prob-
ability in both groups and the Logrank test was used to
compare rates of death due to uremic crisis between groups.
In addition, the Kaplan-Meier was used to evaluate the
probability of maintaining stable serum creatinine (serum
creatinine concentration not increased above 20% compared
to randomization time) in both groups, and the Logrank test4 The Scientiﬁc World Journal
Table 3: Mean, median, and 25% and 75% percentile for BW and BCS, hematocrit, serum creatinine, BUN, phosphate, blood pH,
bicarbonate, and UPC ratio, for group B at time of randomization (T0) and after 4–8 weeks (T1) of treatment. Diﬀerences between values
at diﬀerent examinations are depicted by P value (statistically signiﬁcant P<0.05).
T0 T1 P value (T0 Versus T1)
BW (kg)
mean 21.0 23.9
median 17.8 23.0 0.06
25% percentile; 75% percentile (9.7; 29.9) (9.5; 33.9)
BSC (1–5)
mean 2.7 2.8
median 3.0 3.0 1.00
25% percentile; 75% percentile (2.0; 3.0) (2.5; 3.0)
Serum Creatinine (mg/dL)
mean 4.9 4.4
median 4.1 3.4 0.50
25% percentile; 75% percentile (2.1; 7.23) (1.7; 6.0)
BUN (mg/dL)
mean 86.2 87.6
median 75.1 63.3 0.55
25% percentile; 75% percentile (42.9; 150.1) (55.0; 77.0)
Phosphorus (mg/dL)
mean 7.1 6.9
median 7.2 5.4 0.87
25% percentile; 75% percentile (5.0; 9.5) (4.2; 10.7)
Blood pH
mean 7.29 7.30
median 7.34 7.30 0.69
25% percentile; 75% percentile (7.20; 7.39) (7.25; 7.40)
HCO3− (mEq/L)
mean 18.4 19.8
median 18.2 20.5 0.20
25% percentile; 75% percentile (14.6; 22.7) (16.1; 22.6)
Hct (%)
mean 32.1 34.2
median 33.0 34.0 0.49
25% percentile; 75% percentile (24.5; 41.0) (29.6; 40.7)
UPC ratio
mean 0.62 0.58
median 0.39 0.3 0.39
25% percentile; 75% percentile (0.29; 0.80) (0.25; 0.79)
was used to compare rates of creatinine variation between
groups.Statisticalanalysiswasperformedwithacommerciall
software, using the intention-to-treat principle. Signiﬁcance
was deﬁned as P<0.05.
3. Results
3.1. Dogs and Groups. Thirty-one dogs were enrolled in the
study. The median age of all dogs was 6 years (range 10
months–13 years). The median age of dogs in group A was
5 years. The median age of dogs in group B was 7 years. Four
dogs were intact females, 16 were spayed females, 11 were
males. Seven dogs were mixed breed, 2 each Dalmatian, Ger-
man Shepherd, and Boxer, 1 each Beagle, Boxer, Cavalier
King Charles Spaniel, American Pittbull, Dobermann, Gold-
en Retriever, Labrador Retriever, Rottweiler, Border Collie,
Bullmastiﬀ, English Bulldog, English Cocker, English Setter,
Greyhound,IrishWolfhound,York-ShireTerrier,andMinia-
ture Poodle.
Fifteen dogs were allocated in group A, and 16 in group
B. At the time of allocation, there was no statistical diﬀerence
between groups with regard to BW and BCS, hematocrit,
serum creatinine, BUN, phosphate, blood pH, bicarbonate,
and UPC ratio (Table 2).
Four dogs in both groups had arterial pressure (AP)
in substage 3 of the IRIS staging system [12]a n dw e r e
treatedwithoralamlodipine(Norvasc,PﬁzerManufacturing
Deutschland GmbH, Illertissen, Germany). Five dogs inThe Scientiﬁc World Journal 5
Table 4: Mean, median, 25% and 75% percentile for BW and BCS, hematocrit, serum creatinine, BUN, phosphate, blood pH, bicarbonate,
and UPC ratio, for group A at time of randomization (T0) and after 4–8 weeks (T1) of treatment. Diﬀerence between values at diﬀerent
examinations are depicted by P-value (statistically signiﬁcant P<0.05).
T0 T1 P value (T0 Versus T1)
BW (kg)
mean 18.2 24.4 0.66
median 14.4 27.9
25% percentile; 75% percentile (8.5; 29.0) (18.1; 31.9)
BSC (1–5)
mean 2.8 3.2 1.00
median 3.0 3.0
25% percentile; 75% percentile (3.0; 3.0) (3.0; 4.0)
Serum Creatinine (mg/dL)
mean 5.7 4.2 0.77
median 3.1 2.0
25% percentile; 75% percentile (1.9; 10.5) (1.5; 5.8)
BUN (mg/dL)
mean 97.1 77.0
median 69.0 32.8 0.54
25% percentile; 75% percentile (32.2; 204.0) (18.9; 121.6)
Phosphorus (mg/dL)
mean 8.9 6.6
median 7.2 5.5 0.97
25% percentile; 75% percentile (5.4; 11.0) (4.7; 7.8)
Blood pH
mean 7.30 7.32
median 7.30 7.30 0.65
25% percentile; 75% percentile (7.25; 7.40) (7.30; 7.35)
HCO3− (mEq/L)
mean 18.9 20.2
median 19.1 19.5 0.43
25% percentile; 75% percentile (16.0; 23.4) (16.3; 24.4)
Hct (%)
mean 30.7 38.7
median 34.0 40.0 0.40
25% percentile; 75% percentile (24.6; 39.0) (28.8; 45.3)
UPC ratio
mean 2.90 1.39
median 0.68 0.55 0.54
25% percentile; 75% percentile (0.24; 1.60) (0.26; 0.70)
GroupAand6dogsinGroupBhadlowserumalbuminlevel
(serum albumin concentration ≤ 2 . 0g / d L )a n dr e c e i v e do r a l
acetylsalicylic acid at 2.0mg/kg q 24hr.
3.2. Followup: BW and BCS, Hematocrit, Serum Creatinine,
BUN, Phosphate, Blood pH, Bicarbonate, Potassium, Calcium,
and UPC Ratio. When values recorded at 4–8 weeks follow-
ing supplement administration were compared with those
collectedatrandomizationtime,inbothgroups,therewasan
improvement for mean serum concentrations of creatinine,
BUN, phosphate, bicarbonate, and results of venous blood
gas analysis, but it was statistically insigniﬁcant (Tables 3
and 4). Potassium and calcium remained stable in both
groups A and B, and no episodes of hyperkalemia or of
hypercalcemiawereidentiﬁedduringthestudyperiod.There
were a signiﬁcant increase in BW in group B 4–8 weeks
following enrolment (Table 3).
3.3.AssociationsbetweenDietarySupplementsandSerumCre-
atinine or Death for Uremic Crises. There was a statistically
signiﬁcant diﬀerence (P = 0.0063; chi-square = 7.44; 95%
CI 0.1231 to 0.8615) between groups A and B regarding the
probability of maintaining stable level of serum creatinine,
with a median period of 16 weeks for group A and 32 weeks
for group B (Figure 1(a)). By the end of the study, 9 out of
15 dogs in group A were dead (8 for uremic crises), against 66 The Scientiﬁc World Journal
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Figure 1: (a) Kaplan-Meier evaluating the probability of maintaining stable level of serum creatinine in treatment group B and in placebo
groupA. Legend: C:placebo controlgroup A; T:treatment group B. (b) Survival curves (death from renal causes) in CKDdogs in IRISstages
2, 3, and 4 in treatment group B and in placebo control group A. Legend: C: placebo control group A; T: treatment group B.
out of 16 in group B (5 for uremic crises). Median survival of
dogs in group B was 42 weeks and was signiﬁcantly longer
than in the control group, with a median survival of 16
weeks (P = 0.0015; chi-square = 5.88; 95% CI 0.1093 to
0.9476)(Figure 1(b)).Nonrenalcausesofdeathincludedone
case of aspiration pneumonia in group B, and in group A
one dog died because of metastatic hemangiosarcoma. The
percentage of deaths due to nonrenal causes did not diﬀer
between groups.
4. Discussion
In a previously published study, admission concentration
of serum creatinine did not inﬂuence survival in dogs with
spontaneous CKD if an RD was administered [1]. Indeed,
median survival for 21 dogs fed an RD and with a mean
serum creatinine concentration of 3.3mg/dL was 615 days,
and median survival for dogs with serum creatinine between
2.0 and 3.1mg/dL was also 615 days [1]. Diﬀerently, among
17 dogs fed a maintenance diet, median survival for dogs
with a mean serum creatinine of 3.7mg/dL was of only
252 days, whereas that of the subpopulation with serum
creatinine between 2.0 and 3.1mg/dL was 461 days [1].
In the present investigation, all dogs were fed an RD,
and the mean serum creatinine concentration at the time
of randomization was 5.7mg/dL in group A and 4.9mg/dL
in group B. After 336 days of treatment, 10 out of 16 dogs
in group B were alive, compared to 6 out of 15 dogs in
group A, with a median survival time of 42 and 16 weeks,
respectively (P = 0.0015), suggesting that chitosan together
with alkalinizing agents are useful in maintaining long-term
good clinical conditions in dogs, similar to previous studies
performed in humans and cats [8–10]. In addition, the
beneﬁcial eﬀect of the dietary supplement was evident
on renal function which was stable, based on creatinine
concentration, twice as much longer in group B compared
to group A (P = 0.0063). It is worth mentioning that the
improvement of blood analytes observed in the placebo-
treated group A after 4–8 weeks of treatment was biased by 3
dogs that died due to severe renal failure and were therefore
not included in the analysis. In contrast, none of the dogs
in group B had died by 4–8 weeks and was excluded from
analysis.
In humans, two possible explanations have been pro-
posed for the reduction of serum concentrations of nitro-
gen metabolites, including their increased clearance due
to compensatory hypertrophy of the remaining nephrons,
and their enhanced excretion bound to chitosan in the
digestive tract [8, 15]. Furthermore, it has been reported
that chitosan can combine with acidic substances suspected
to be uremic toxins, resulting in their greater excretion
from the body, thus in improved clinical conditions [8, 16];
whether these same eﬀects are exerted in dogs has not
been studied but the present results may suggest that one
or more of these mechanisms operate also in this species.
Furthermore, because the supplement contains diﬀerent
substances,itcannot be excludedthatphosphatebinders and
alkalinizing agents, or their combination, are active against
uremic toxins rather than chitosan. In summary, the present
study shows the beneﬁcial eﬀect of a commercial dietary
supplement including chitosan, enteric phosphate binders,
and alkalinizing agents in dogs aﬀectedby spontaneous CKDThe Scientiﬁc World Journal 7
in IRIS stages 2, 3, and 4, fed an RD. The fact that serum
creatinine concentration was signiﬁcantly more stable and
for a longer period of time in dogs receiving the supplement
(Group B) is consistent with the hypothesis that delay in
development of uremic crises and associated mortality rate
was related, at least in part, with a reduction in the progres-
sion of renal failure.
Abbreviations
CKD: Chronic kidney disease
RD: Renal diet
IRIS: International Renal Interest Society
BW: Body weight
BCS: Body condition score
BUN: Blood urea nitrogen
UPC: Urine protein–to-creatinine
AP: Arterial pressure
RR: Relative risk
95% CI: 95% conﬁdence interval.
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